Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
about
New approaches to understanding the immune response to vaccination and infectionInflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy womenComparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particlesImmune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model.Flow cytometry and the future of vaccine development.Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomavirusesInfluence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses.Trigger factor assisted self-assembly of canine parvovirus VP2 protein into virus-like particles in Escherichia coli with high immunogenicity.Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response
P2860
Q26800283-0B23E0E7-62F5-476B-95AA-918F7F73B20AQ30370026-C390428F-938B-4CD0-AD38-9C6216DC32DCQ33626980-1B072631-1B1B-455A-9DFE-A422C2D7DFD1Q33768747-82024149-AB6C-4684-9995-265D36FE11ABQ33780842-1745A87E-A690-4DAB-9463-FC5CBF89548DQ34019891-79F2831C-1A2E-4D5E-95DA-59E817322AB8Q35886468-0EEF4726-0303-4142-B963-B01F4073F9A5Q37033232-C284F315-CDF6-4DCB-9133-165535AF649DQ37440864-4FBFF6CD-F691-4FAF-9F8F-64558DC1B714Q37503257-706D20BD-59EB-4BA4-9486-81AF25CA93E1Q39793237-9827E075-77F5-4FB0-9FEE-D01D8E553DDDQ42193505-559ABCE9-A728-4415-BDAA-D1C8A26EEE5AQ43246232-75864426-2977-4A21-9785-482B680CA427Q55487393-607BC1B3-9950-4A26-9518-C65F32607638Q58167989-28712088-E654-43CA-A4BC-8117B3D03FA3
P2860
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@ast
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@en
type
label
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@ast
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@en
prefLabel
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@ast
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@en
P2093
P2860
P356
P1476
Cytokine and chemokine profile ...... pe 16 L1 Virus-like particles.
@en
P2093
Alfonso García-Piñeres
Clayton Harro
Douglas R Lowy
John T Schiller
Ligia A Pinto
Marcus Williams
Troy J Kemp
P2860
P304
P356
10.1128/CVI.00090-07
P577
2007-06-27T00:00:00Z